Welcome to Multibagg AI
Log in to access personalized features
Portfolio
Alerts
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discovery themes featuring this stock
Onyx Biotec Limited, founded in 2005, is a pharmaceutical manufacturer specializing in sterile water for injections, dry powder injections, and dry syrup, catering to both Indian and global markets.
The company boasts robust manufacturing capabilities with two manufacturing units in Solan, Himachal Pradesh, offering a combined capacity of over 230 million units annually.
A significant capacity expansion was achieved in 2017-18, followed by the commencement of Unit II's commercial production in 2023, boosting their production capabilities.
Onyx is preparing for an IPO with the issuance of 48,10,000 fresh equity shares, indicating growth ambitions in capital markets.
Their core service offering includes end-to-end product development and regulatory dossier preparation for pharmaceutical clients, positioning Onyx as a comprehensive contract manufacturing partner.
Pharmaceuticals & Biotechnology
Pharmaceuticals
68 Cr
Low Risk
-324.2
37.7
—
1.2
50.00
24.20
Sales CAGR
Profit CAGR
ROE
ROCE
Onyx Biotec Ltd (ONYX) is currently trading at 37.50 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Onyx Biotec Limited, founded in 2005, is a pharmaceutical manufacturer specializing in sterile water for injections, dry powder injections, and dry syrup, catering to both Indian and global markets. The company boasts robust manufacturing capabilities with two manufacturing units in Solan, Himachal Pradesh, offering a combined capacity of over 230 million units annually. A significant capacity expansion was achieved in 2017-18, followed by the commencement of Unit II's commercial production in 2023, boosting their production capabilities. Onyx is preparing for an IPO with the issuance of 48,10,000 fresh equity shares, indicating growth ambitions in capital markets. Their core service offering includes end-to-end product development and regulatory dossier preparation for pharmaceutical clients, positioning Onyx as a comprehensive contract manufacturing partner.
Over the past 52 weeks, Onyx Biotec Ltd has traded between a low of ₹24.20 and a high of ₹50.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Onyx Biotec Ltd has a market capitalization of approximately 68.09. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Onyx Biotec Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of -324.24 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 68.09 Cr, Onyx Biotec Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Onyx Biotec Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Onyx Biotec Ltd is -324.24. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Bearish
3
Neutral
3
Bullish
8
Bearish
33
Neutral
3
Bullish
10
Bearish
30
Neutral
0
Bullish
2
Bearish
3
Neutral
3
Bullish
8
Bearish
3
Neutral
3
Bullish
8
Bearish
30
Neutral
0
Bullish
2
Bearish
30
Neutral
0
Bullish
2
Bearish
30
Neutral
0
Bullish
2
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
37.09 | 71 Cr | 64.39 | 1.57 | 0.00 | 2.44 | 6.78 | 0.89 | ||
233.45 | 71 Cr | -32.27 | 1.05 | 0.00 | -4.86 | -2.57 | -1.78 | ||
109.75 | 68 Cr | 19.52 | 9.02 | 0.00 | — | — | 0.00 | ||
37.50 | 68 Cr | -324.24 | 1.23 | 0.00 | -0.39 | 1.12 | -0.22 | ||
15.24 | 65 Cr | -3.59 | 0.00 | 0.00 | -22.95 | -11.16 | -9.61 | ||
57.10 | 62 Cr | -188.61 | 16.12 | 0.00 | 20.74 | -104.17 | -27.73 | ||
88.00 | 60 Cr | 3.39 | 2.71 | 0.00 | 8.93 | 11.29 | 58.72 | ||
| Median: 7 Co. | — | 57.10 | 68 Cr | -3.59 | 1.57 | 0.00 | 1.02 | -0.72 | -0.22 |
AGM/EGM Notice
Onyx Biotec Ltd informed the exchange that a newspaper cutting was published disclosing the Notice of the AGM and e-voting details (published in Financial Express and Dainik Savera).
Board Meeting
Onyx Biotec Ltd: Board approved 21st AGM on 2026-09-28 (VC/OAVM), book closure 2026-09-22 to 2026-09-28, cut-off 2026-09-21, appointed scrutinizer and cost auditor, and changed Naresh Kumar's designation to Managing Director (effective 2026-09-03, subject to shareholder approval).
